Another important study in APP/PS1 mice demonstrated that EGCG may reduce Aβ levels and ameliorate cognitive impairment via two putative mechanisms: (1) neurogenesis induction via nerve growth factor (NGF)-Tropomyosin receptor kinase A (TrkA) pathway activation, which regulates c-Raf/ERK1-2/CREB cascade; (2) apoptosis inhibition, via suppression of pro-apoptotic full length neurotrophin receptor (p75NTR)/intracellular domain fragment neurotrophin receptor (p75ICD) and reduction of JNK2/cleaved-caspase 3 activity [82]. Here, NTRK1 is linked to Cognitive impairment.